Device Trial Radar · NCT07147218
Accelerated TMS for MDD
Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
50
Actual
Start
Aug 21, 2025
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- NeuroneticsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 29, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, multi-center, prospective study to evaluate feasibility and efficacy of accelerated TMS for patients with Major Depressive Disorder (MDD).
Conditions
- Major Depressive Disorder
Interventions
TMSDevice
transcranial magnetic stimulation - DASH 36 treatment delivered in 5 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in MADRS score from baseline to post-treatment.Time frame: 2 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Brighter Neurotherapeutics
New York, New York
TMS of the Carolinas
Charlotte, North Carolina
New chapter TMS
Spokane, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.